You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Alosetron was effective and safe for relieving abdominal symptoms in women with irritable bowel syndrome

https://doi.org/10.1136/ebm.6.1.21

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2000) Lancet 355, 1035. Camilleri M, Northcutt AR, Kong S. , et al.. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.. Mar 25;. :. –40. .
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: What is the effectiveness and safety of alosetron in women with irritable bowel syndrome (IBS)?

    Design

    Randomised (allocation concealed*), blinded (clinicians, patients, outcome assessors, and statisticians),* placebo controlled trial for 12 weeks with 1 month follow up.

    Setting

    119 centres in the US.

    Patients

    647 women ≥18 years of age (mean age 46 y, 93% white) who had IBS for ≥6 months, had normal colonic anatomy, were diarrhoea predominant or had alternating bowel patterns (diarrhoea and constipation), had a mean daily abdominal pain and discomfort score between 1.0 and 3.3 on a 5 point scale (0=none to 4=severe), and a mean daily stool consistency score ≥2.5 on a 5 point scale (1=very hard to 5=watery). Exclusion criteria were constipation predominant IBS; pregnancy, breast feeding, or potential for childbearing; unstable medical or other gastrointestinal disorder; major psychiatric disorder; substance abuse in the previous 2 years; abnormal aspartate aminotransferase, alanine aminotransferase, or serum creatinine concentrations; hyperthyroidism or hypothyroidism; non-skin malignancy in the previous 5 years; investigational drug use 30 days before study; or use of …

    View Full Text

    Footnotes

    • Source of funding: Glaxo Wellcome Research and Development.

    • For correspondence: Dr A W Mangel, Gastroenterology Clinical Development, Glaxo Wellcome, Research Triangle Park, NC 27709, USA. Fax +1 919 483 8614.

    • ↵* See glossary.

    • ↵† p Values calculated from data in article.